-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since February, the 2021 annual reports of two listed pharmaceutical and biological companies have been disclosed one after another
.
Up to now, Dizhe Medicine, Rejing Bio, Kexing Pharmaceutical, Tesson Medical, Nanxin Pharmaceutical, Haohai Biotechnology, Xinhecheng, etc.
have released performance reports first, among which 5 reported good news, 2 lost money, and 1 Turn from profit to loss
.
From the perspective of net profit growth, Rejing Bio has increased by more than 10 times
.
And recently, another pharmaceutical company showed its 2021 transcript! On March 2, the Hong Kong-listed pharmaceutical company Zai Lab-SB released its 2021 results announcement.
In 2021, the group achieved total revenue of US$144 million, a year-on-year increase of 194.
77%; R&D expenditure was US$573 million, a year-on-year increase of 157.
42%; common stock The net loss attributable to shareholders was US$704 million, a year-on-year increase of 161.
98%; the loss per share was US$7.
58
.
According to the announcement, the increase in R&D expenditure in 2021 is mainly due to the advance payment of eight newly signed license agreements, the related expenses of ongoing and newly launched late-stage clinical studies, the salaries of additional R&D personnel and the increase in salary-related expenses
.
Excluding upfront payments for newly signed license agreements, core R&D spending in 2021 was $252 million compared to $139.
2 million in the same period in 2020
.
It is understood that under the steady growth of R&D investment in 2021, the company has consolidated a product pipeline consisting of many potential first-in-class and potential Best-in-Class
.
At present, the company has 11 in-house R&D drugs with global rights and has made important R&D progress.
Among them, the anti-IL-17A Humabody® ZL-1102 for the treatment of chronic plaque psoriasis has achieved proof-of-concept
.
The company plans to bring medicines to patients faster by expediting critical data interpretation and registration applications across all product pipelines
.
It will continue to invest in R&D and advance its in-house pipeline with global rights to achieve its mission of benefiting patients around the world
.
In addition, Zai Lab will continue to strengthen and strengthen the team in 2021
.
The new employees who have joined since November 2021 include Dr.
Linda Liu, Senior Vice President of Biopharmaceutical Discovery, Dr.
Hua Gong, Senior Vice President of Translational Medicine, and Dr.
Jing Cao, Vice President of Program Management in the Central Nervous System, Autoimmunity and Anti-Infection Fields, etc.
.
As of January 31, 2022, Zai Lab had 1,951 full-time employees, of which 788 and 945 were in R&D and commercialization positions, respectively
.
Going forward, the company aims to have at least 15 products on the market by 2025, covering more than 30 indications
.
The company believes that the policy environment will continue to be favorable for innovative biopharmaceutical companies such as Zai Lab
.
Current forecasts project total peak sales of the company's existing pipelines in lung cancer and gastrointestinal oncology to be as high as $2.
5 billion to $3 billion by 2030
.
For the full year of 2021, the increase in Zai Lab's loss was mainly attributable to expenses related to new business development activities
.
Excluding prepayments for newly signed license agreements, the company's cash expenditures for operating activities, purchases of property and equipment, and intangible assets in 2021 were approximately $309.
2 million, compared with approximately $143.
2 million in the same period in 2020
.
Cash and cash equivalents, short-term investments and restricted cash totaled $1,409.
9 million as of December 31, 2021, compared to $1,187.
5 million as of December 31, 2020
.
Zai Lab is an innovative, patient-centric, commercial-stage global biopharmaceutical company dedicated to addressing the unmet needs of oncology, autoimmunity, infectious diseases and the central nervous system through the development and commercialization of innovative therapeutics medical needs
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Up to now, Dizhe Medicine, Rejing Bio, Kexing Pharmaceutical, Tesson Medical, Nanxin Pharmaceutical, Haohai Biotechnology, Xinhecheng, etc.
have released performance reports first, among which 5 reported good news, 2 lost money, and 1 Turn from profit to loss
.
From the perspective of net profit growth, Rejing Bio has increased by more than 10 times
.
And recently, another pharmaceutical company showed its 2021 transcript! On March 2, the Hong Kong-listed pharmaceutical company Zai Lab-SB released its 2021 results announcement.
In 2021, the group achieved total revenue of US$144 million, a year-on-year increase of 194.
77%; R&D expenditure was US$573 million, a year-on-year increase of 157.
42%; common stock The net loss attributable to shareholders was US$704 million, a year-on-year increase of 161.
98%; the loss per share was US$7.
58
.
According to the announcement, the increase in R&D expenditure in 2021 is mainly due to the advance payment of eight newly signed license agreements, the related expenses of ongoing and newly launched late-stage clinical studies, the salaries of additional R&D personnel and the increase in salary-related expenses
.
Excluding upfront payments for newly signed license agreements, core R&D spending in 2021 was $252 million compared to $139.
2 million in the same period in 2020
.
It is understood that under the steady growth of R&D investment in 2021, the company has consolidated a product pipeline consisting of many potential first-in-class and potential Best-in-Class
.
At present, the company has 11 in-house R&D drugs with global rights and has made important R&D progress.
Among them, the anti-IL-17A Humabody® ZL-1102 for the treatment of chronic plaque psoriasis has achieved proof-of-concept
.
The company plans to bring medicines to patients faster by expediting critical data interpretation and registration applications across all product pipelines
.
It will continue to invest in R&D and advance its in-house pipeline with global rights to achieve its mission of benefiting patients around the world
.
In addition, Zai Lab will continue to strengthen and strengthen the team in 2021
.
The new employees who have joined since November 2021 include Dr.
Linda Liu, Senior Vice President of Biopharmaceutical Discovery, Dr.
Hua Gong, Senior Vice President of Translational Medicine, and Dr.
Jing Cao, Vice President of Program Management in the Central Nervous System, Autoimmunity and Anti-Infection Fields, etc.
.
As of January 31, 2022, Zai Lab had 1,951 full-time employees, of which 788 and 945 were in R&D and commercialization positions, respectively
.
Going forward, the company aims to have at least 15 products on the market by 2025, covering more than 30 indications
.
The company believes that the policy environment will continue to be favorable for innovative biopharmaceutical companies such as Zai Lab
.
Current forecasts project total peak sales of the company's existing pipelines in lung cancer and gastrointestinal oncology to be as high as $2.
5 billion to $3 billion by 2030
.
For the full year of 2021, the increase in Zai Lab's loss was mainly attributable to expenses related to new business development activities
.
Excluding prepayments for newly signed license agreements, the company's cash expenditures for operating activities, purchases of property and equipment, and intangible assets in 2021 were approximately $309.
2 million, compared with approximately $143.
2 million in the same period in 2020
.
Cash and cash equivalents, short-term investments and restricted cash totaled $1,409.
9 million as of December 31, 2021, compared to $1,187.
5 million as of December 31, 2020
.
Zai Lab is an innovative, patient-centric, commercial-stage global biopharmaceutical company dedicated to addressing the unmet needs of oncology, autoimmunity, infectious diseases and the central nervous system through the development and commercialization of innovative therapeutics medical needs
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
